ASND Rises 4.5% on Week 104 ApproaCH Trial Data

Ascendis Pharma A/S (ASND) rose 4.5% on Jul 8, 2026 after the company shared radiographic data from Week 104 of its pivotal ApproaCH trial of TransCon CNP in children with achondroplasia.

What Ascendis Pharma announced

Ascendis said it is presenting radiographic (imaging) data from Week 104 of the pivotal ApproaCH clinical trial evaluating TransCon CNP in children with achondroplasia. The update is tied to ICCBH 2026, signaling the company is putting longer-term trial readouts in front of the medical and investor community. In plain English: this is a look at how bones are developing over a longer stretch of time in children receiving the therapy, using X-ray-style measures rather than just shorter-term snapshots.

The company also framed the release as “for investor communication only,” emphasizing it’s not meant as promotional material.

What it means for Ascendis Pharma

Longer-term radiographic data can matter because it speaks to durability — whether changes seen earlier in a study appear to hold up over time when you look at the underlying skeletal structure. By highlighting Week 104 results from a pivotal trial, Ascendis is positioning TransCon CNP’s data package as more mature, which could help stakeholders evaluate the program’s longer-run profile.

Because the announcement is specifically about radiographic data, it also suggests the company is leaning into objective, imaging-based endpoints that can add context to how a treatment may be affecting growth-related outcomes in achondroplasia. At a minimum, presenting these results at a conference keeps the program in the spotlight and can shape how the market thinks about the depth of the evidence behind TransCon CNP.

How the stock reacted

ASND started with a small early move and then built on gains through the session.

Window	Move
5 min	+0.3%
10 min	+0.6%
30 min	+2.5%
1 hour	+1.8%
end of day	+4.5%

On a market-adjusted basis, the stock’s same-day excess return versus SPY was +4.1%.